Ferreira, E.V.M.; Oliveira, R.K.F.; Salomao, R.; Brunialti, M.K.C.; Cardoso, M.B.A.; Chen, C.-n.; Zhao, L.; McCabe, C.
Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling. Infect. Dis. Rep. 2025, 17, 5.
https://doi.org/10.3390/idr17010005
AMA Style
Ferreira EVM, Oliveira RKF, Salomao R, Brunialti MKC, Cardoso MBA, Chen C-n, Zhao L, McCabe C.
Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling. Infectious Disease Reports. 2025; 17(1):5.
https://doi.org/10.3390/idr17010005
Chicago/Turabian Style
Ferreira, Eloara V. M., Rudolf K. F. Oliveira, Reinaldo Salomao, Milena K. C. Brunialti, Martyella B. A. Cardoso, Chien-nien Chen, Lan Zhao, and Colm McCabe.
2025. "Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling" Infectious Disease Reports 17, no. 1: 5.
https://doi.org/10.3390/idr17010005
APA Style
Ferreira, E. V. M., Oliveira, R. K. F., Salomao, R., Brunialti, M. K. C., Cardoso, M. B. A., Chen, C.-n., Zhao, L., & McCabe, C.
(2025). Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling. Infectious Disease Reports, 17(1), 5.
https://doi.org/10.3390/idr17010005
